Approaching solid tumor heterogeneity on a cellular basis by tissue proteomics using laser capture microdissection and biological mass spectrometry

Journal of Proteome Research

Volumn 8, Issue 5, 2009, Pages 2310-2318

  Johann Jr , Donald J ^a   Rodriguez Canales, Jaime ^a   Mukherjee, Sumana ^b   DaRue A Prieto, ^a   Hanson, Jeffrey C ^a   Emmert Buck, Michael ^a,b   Blonder, Josip ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Laser capture microdissection (LCM); Mass spectrometry (MS); Solid tumor heterogeneity

Indexed keywords

BIOLOGICAL MARKER; TUMOR PROTEIN;

ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CELL HETEROGENEITY; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LIQUID CHROMATOGRAPHY; LYMPH NODE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; SOLID TUMOR; TANDEM MASS SPECTROMETRY;

EID: 66749148302     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr8009403     Document Type: Article

References (37)

1. Liotta, L. A.; Kohn, E. C. The microenvironment of the tumour- host interface. Nature (London) 2001, 411 (6835), 375-9.
2. Heppner, G. H.; Miller, B. E. Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev . 1983, 2 (1), 5-23.
3. Zang, L.; Palmer Toy, D.; Hancock, W. S.; Sgroi, D. C.; Karger, B. L. Proteomic analysis of ductal carcinoma of the breast using laser capture microdissection, LC-MS, and 16O/18O isotopic labeling. J. Proteome Res . 2004, 3 (3), 604-12.
4. Gu, Y.; Wu, S. L.; Meyer, J. L.; Hancock, W. S.; Burg, L. J.; Linder, J.; Hanlon, D. W.; Karger, B. L. Proteomic analysis of high-grade dysplastic cervical cells obtained from ThinPrep slides using laser capture microdissection and mass spectrometry. J. Proteome Res . 2007, 6 (11), 4256-68.
5. Umar, A.; Luider, T. M.; Foekens, J. A.; Pasa-Tolic, L. NanoLC-FT-ICR MS improves proteome coverage attainable for approximately 3000 laser-microdissected breast carcinoma cells. Proteomics 2007, 7 (2), 323-9.
6. Hwang, S. I.; Thumar, J.; Lundgren, D. H.; Rezaul, K.; Mayya, V.; Wu, L.; Eng, J.; Wright, M. E.; Han, D. K. Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues. Oncogene 2007, 26 (1), 65-76.
7. Bagnato, C.; Thumar, J.; Mayya, V.; Hwang, S. I.; Zebroski, H.; Claffey, K. P.; Haudenschild, C.; Eng, J. K.; Lundgren, D. H.; Han, D. K. Proteomics analysis of human coronary atherosclerotic plaque: a feasibility study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry. Mol. Cell. Pro- teomics 2007, 6 (6), 1088-102.
8. Baker, H.; Patel, V.; Molinolo, A. A.; Shillitoe, E. J.; Ensley, J. F.; Yoo, G. H.; Meneses-Garcia, A.; Myers, J. N.; El-Naggar, A. K.; Gutkind, J. S.; Hancock, W. S. Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissec- tion and tandem mass spectrometry. Oral Oncol . 2005, 41 (2), 183-99.
9. Li, C.; Hong, Y.; Tan, Y. X.; Zhou, H.; Ai, J. H.; Li, S. J.; Zhang, L.; Xia, Q. C.; Wu, J. R.; Wang, H. Y.; Zeng, R. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol. Cell. Proteomics 2004, 3 (4), 399-409.
10. Emmert-Buck, M. R.; Strausberg, R. L.; Krizman, D. B.; Bonaldo, M. F.; Bonner, R. F.; Bostwick, D. G.; Brown, M. R.; Buetow, K. H.; Chuaqui, R. F.; Cole, K. A.; Duray, P. H.; Englert, C. R.; Gillespie, J. W.; Greenhut, S.; Grouse, L.; Hillier, L. W.; Katz, K. S.; Klausner, R. D.; Kuznetzov, V.; Lash, A. E.; Lennon, G.; Linehan, W. M.; Liotta, L. A.; Marra, M. A.; Munson, P. J.; Ornstein, D. K.; Prabhu, V. V.; Prang, C.; Schuler, G. D.; Soares, M. B.; Tolstoshev, C. M.; Vocke, C. D.; Waterston, R. H. Molecular profiling of clinical tissues specimens: feasibility and applications. J. Mol. Diagn 2000, 2 (2), 60-6.
11. Blonder, J.; Chan, K. C.; Issaq, H. J.; Veenstra, T. D. Identification of membrane proteins from mammalian cell/tissue using methanol- facilitated solubilization and tryptic digestion coupled with 2D- LC-MS/MS. Nat. Protoc . 2006, 1 (6), 2784-90.
12. Gupta, G. P.; Massague, J. Cancer metastasis: building a framework. Cell 2006, 127 (4), 679-95.
13. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100 (1), 57-70.
14. Campbell, L. L.; Polyak, K. Breast tumor heterogeneity: cancer stem cells or clonal evolution. Cell Cycle 2007, 6 (19), 2332-8.
15. Bloushtain-Qimron, N.; Yao, J.; Snyder, E. L.; Shipitsin, M.; Campbell, L. L.; Mani, S. A.; Hu, M.; Chen, H.; Ustyansky, V.; Antosiewicz, J. E.; Argani, P.; Halushka, M. K.; Thomson, J. A.; Pharoah, P.; Porgador, A.; Sukumar, S.; Parsons, R.; Richardson, A. L.; Stampfer, M. R.; Gelman, R. S.; Nikolskaya, T.; Nikolsky, Y.; Polyak, K. Cell type-specific DNA methylation patterns in the human breast. Proc. Natl. Acad. Sci. U.S.A . 2008, 105 (37), 14076-81.
16. Shipitsin, M.; Campbell, L. L.; Argani, P.; Weremowicz, S.; Bloush- tain-Qimron, N.; Yao, J.; Nikolskaya, T.; Serebryiskaya, T.; Ber- oukhim, R.; Hu, M.; Halushka, M. K.; Sukumar, S.; Parker, L. M.; Anderson, K. S.; Harris, L. N.; Garber, J. E.; Richardson, A. L.; Schnitt, S. J.; Nikolsky, Y.; Gelman, R. S.; Polyak, K. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11 (3), 259-73.
17. Ignatiadis, M.; Kallergi, G.; Ntoulia, M.; Perraki, M.; Apostolaki, S.; Kafousi, M.; Chlouverakis, G.; Stathopoulos, E.; Lianidou, E.; Georgoulias, V.; Mavroudis, D. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin. Cancer Res . 2008, 14 (9), 2593-600.
18. Sato, T.; Kaneko, T.; Ikeda, T.; Nagai, T.; Makino, H.; Sano, M.; Shima, Y. Diversity of keratin 19 gene expressed in lymph nodes of breast cancer patients. Strategy to clear the discrepancy between histological findings and RT-PCR result in the detection of micrometastasis. Jpn. J. Electrophor . 2000, 44 (3), 201-04.
19. Silva, J. M.; Dominguez, G.; Silva, J.; Garcia, J. M.; Sanchez, A.; Rodriguez, O.; Provencio, M.; Espana, P.; Bonilla, F. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin. Cancer Res . 2001, 7 (9), 2821-5.
20. Russo, J.; Moral, R.; Balogh, G. A.; Mailo, D.; Russo, I. H. The protective role of pregnancy in breast cancer. Breast Cancer Res . 2005, 7 (3), 131-132.
21. Eilon, T.; Barash, I. Different gene-expression profiles for the poorly differentiated carcinoma and the highly differentiated papillary adenocarcinoma in mammary glands support distinct metabolic pathways. BMC Cancer 2008, 8 , 270.
22. Horton, R.; Wilming, L.; Rand, V.; Lovering, R. C.; Bruford, E. A.; Khodiyar, V. K.; Lush, M. J.; Povey, S.; Talbot, C. C., Jr.; Wright, M. W.; Wain, H. M.; Trowsdale, J.; Ziegler, A.; Beck, S. Gene map of the extended human MHC. Nat Rev Genet 2004, 5 (12), 889-99.
23. Zhao, H.; Langerod, A.; Ji, Y.; Nowels, K. W.; Nesland, J. M.; Tibshirani, R.; Bukholm, I. K.; Karesen, R.; Botstein, D.; Borresen- Dale, A. L.; Jeffrey, S. S. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol. Biol. Cell 2004, 15 (6), 2523-36.
24. Fraga, M. F.; Ballestar, E.; Villar-Garea, A.; Boix-Chornet, M.; Espada, J.; Schotta, G.; Bonaldi, T.; Haydon, C.; Ropero, S.; Petrie, K.; Iyer, N. G.; Perez-Rosado, A.; Calvo, E.; Lopez, J. A.; Cano, A.; Calasanz, M. J.; Colomer, D.; Piris, M. A.; Ahn, N.; Imhof, A.; Caldas, C.; Jenuwein, T.; Esteller, M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet . 2005, 37 (4), 391-400.
25. Vandermoere, F.; El Yazidi-Belkoura, I.; Demont, Y.; Slomianny, C.; Antol, J.; Lemoine, J.; Hondermarck, H. Proteomics exploration reveals that actin is a signaling target of the kinase Akt. Mol. Cell. Proteomics 2007, 6 (1), 114-24.
26. Krajewski, S.; Blomqvist, C.; Franssila, K.; Krajewska, M.; Was- enius, V. M.; Niskanen, E.; Nordling, S.; Reed, J. C. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res . 1995, 55 (19), 4471-8.
27. Sjostrom, J.; Blomqvist, C.; von Boguslawski, K.; Bengtsson, N. O.; Mjaaland, I.; Malmstrom, P.; Ostenstadt, B.; Wist, E.; Valvere, V.; Takayama, S.; Reed, J. C.; Saksela, E. The predictive value of bcl- 2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin. Cancer Res . 2002, 8 (3), 811-6.
28. Berx, G.; Cleton-Jansen, A. M.; Nollet, F.; de Leeuw, W. J.; van de Vijver, M.; Cornelisse, C.; van Roy, F. E-cadherin is a tumour/ invasion suppressor gene mutated in human lobular breast cancers. EMBO J . 1995, 14 (24), 6107-15.
29. OMIM; http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgiid=192090.
30. Berx, G.; Becker, K. F.; Hofler, H.; van Roy, F. Mutations of the human E-cadherin (CDH1) gene. Hum. Mutat . 1998, 12 (4), 226-37.
31. Korsching, E.; Packeisen, J.; Liedtke, C.; Hungermann, D.; Wulfing, P.; van Diest, P. J.; Brandt, B.; Boecker, W.; Buerger, H. The origin of vimentin expression in invasive breast cancer: epithelial- mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential. J. Pathol . 2005, 206 (4), 451-7.
32. Kurihara, H.; Yang, D. J.; Cristofanilli, M.; Erwin, W. D.; Yu, D. F.; Kohanim, S.; Mendez, R.; Kim, E. E. Imaging and dosimetry of 99mTc EC annexinV: preliminary clinical study targeting apoptosis in breast tumors. Awl. Radiat. Isot . 2008, 66 (9), 1175-82.
33. Casey, T. M.; Eneman, J.; Crocker, A.; White, J.; Tessitore, J.; Stanley, M.; Harlow, S.; Bunn, J. Y.; Weaver, D.; Muss, H.; Plaut, K. Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-beta 1) increase invasion rate of tumor cells: a population study. Breast Cancer Res. Treat . 2008, 110 (1), 39-49.
34. Tommasi, S.; Mangia, A.; Lacalamita, R.; Bellizzi, A.; Fedele, V.; Chiriatti, A.; Thomssen, C.; Kendzierski, N.; Latorre, A.; Lorusso, V.; Schittulli, F.; Zito, F.; Kavallaris, M.; Paradiso, A. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int. J. Cancer 2007, 120 (10), 2078-85.
35. Stoeckli, M.; Chaurand, P.; Hallahan, D. E.; Caprioli, R. M. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat. Med . 2001, 7 (4), 493-6.
36. Hinestrosa, M. C.; Dickersin, K.; Klein, P.; Mayer, M.; Noss, K.; Slamon, D.; Sledge, G.; Visco, F. M. Shaping the future ofbiomarker research in breast cancer to ensure clinical relevance. Nat. Rev. Cancer 2007, 7 (4), 309-15.
37. Viale, G.; Regan, M. M.; Maiorano, E.; Mastropasqua, M. G.; Dell'Orto, P.; Rasmussen, B. B.; Raffoul, J.; Neven, P.; Orosz, Z.; Braye, S.; Ohlschlegel, C.; Thurlimann, B.; Gelber, R. D.; Castigli- one-Gertsch, M.; Price, K. N.; Goldhirsch, A.; Gusterson, B. A.; Coates, A. S. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J. Clin. Oncol . 2007, 25 (25), 3846-52.